The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Cell and Gene Therapy CROs Market, 2018-2030

  • Lowest Price Guaranteed From USD 3,499

  • Published
    October 2018

  • Pages
    238

  • View Count
    4703

Example Insights

 

 

Overview

In the recent past, cell and gene therapies have emerged as promising treatment options for a myriad of complex clinical conditions, including cancers and inherited disorders. Currently, more than 25 such advanced therapy medicinal products are available in the market; examples of recently approved therapies include Alofisel (2018), LUXTURNA™ (2017), YESCARTA™ (2017), Kymriah™ (2017) and INVOSSA™ (2017). In addition, over 500 cell and gene therapy candidates are being investigated in different stages of clinical development, across various geographies. In fact, in the past five years alone, more than 1,000 clinical trials that are currently active were initiated to evaluate the potential of these therapies across multiple therapeutic indications. Due to several development challenges, such as fragile nature of cells being used, safety and efficacy issues, laborious procedures for conducting clinical studies, complex regulatory framework and exorbitant costs, it is difficult for the companies with limited expertise and finances to successfully develop these therapies in-house. The aforementioned challenges have led several players to outsource a significant part of their clinical stage research to capable contract research organizations (CROs), which claim to offer cost-efficient solutions as well as intellectual and operational expertise.

In fact, various therapy developers have partnered with CROs to seek their support in advancing product candidates towards approval. Moreover, contract service providers have formed alliances to enhance their capabilities and provide an integrated suite of services. It is also worth highlighting that the industry has witnessed some consolidation in the last five years as smaller players have been acquired in an effort to widen the parent company’s geographical reach. Furthermore, service providers have invested in developing / adopting advanced tools, technologies and platforms in order to provide robust and evidence based clinical data for approval. Given these technological advancements, the cost and time-related advantages of outsourcing research and the expanding pipeline of cell and gene therapy candidates, the demand for CROs is projected to grow in the foreseen future.

 

Scope of the Report

The ‘Cell and Gene Therapy CROs Market, 2018-2030’ report features a comprehensive study on the current landscape of contract research service providers in the cell and gene therapy sector. The study presents an in-depth analysis, highlighting the capabilities of stakeholders engaged in this domain, across different regions of the globe. Amongst various elements, the report includes:

  • An assessment of the current market landscape, featuring a comprehensive list of more than 70 active CROs and a detailed analysis based on a number of parameters, such as the company size, location of their headquarters, year of establishment, type of therapy (cell therapy (stem cells, T cells, dendritic cells, NK cells and tumor cells) and gene therapy), scale of operations (scale and preclinical) and types of services offered including [A] clinical services (clinical trial management, clinical trial monitoring, data management and project management, clinical safety and quality studies, regulatory services, consultancy services and IT / informatics services) and [B] preclinical services (bioanalytical services, toxicology studies, in vivo studies, preclinical safety and quality studies and support services).
  • A comprehensive discussion on the various outsourcing business models adopted in this field, along with a list of key considerations that need to be taken into account by therapy developers while selecting a CRO partner.
  • Elaborate profiles of prominent players that offer contract research services for cell and gene therapies; each profile provides an overview of the company, its financial status (if available), information on its service(s) portfolio and a detailed future outlook.
  • A comprehensive benchmark analysis, highlighting the key focus areas of small, mid- and large companies, comparing their existing capabilities within and beyond their respective peer groups, and providing a means for stakeholders to identify ways to gain a competitive edge in the industry.
  • A comprehensive clinical trial analysis of ongoing studies related to the cell and gene therapy candidates in order to estimate the total number of product candidates under clinical evaluation. It provides detailed information related to clinical trials based on various parameters, such as geography, current status of trials, type of cell therapies (stem cells, T cells, dendritic cells, NK cells and tumor cells), key therapeutic area(s), disease indication(s) and number of patients enrolled.
  • A detailed analysis of the recent collaborations (since 2013) focused on the contract services signed for cell and gene therapies based on various parameters, such as the year of establishment, type of agreement, type of services for which the companies partnered, type of cell and gene therapy and geographical location.
  • A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, featuringa Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the overall cell and gene therapy CRO market.

One of the key objectives of this report is to evaluate the current opportunity and the future potential of the cell and gene therapy CROs market over the coming decade. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2018-2030. In addition, we have provided the likely distribution of the market based on [A] type of therapy (cell therapy and gene therapy) [B] scale of operation (clinical and preclinical), [C] type of therapeutic areas (oncology and non-oncology) and [D] geographical region regions (covering North America, Europe, Asia Pacific and rest of the world). To account for the uncertainties associated with the growth of cell and gene therapy CRO market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

All actual figures have been sourced and analyzed from publicly available information forums and inputs from primary research. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view of currentscenario of cell and gene therapy CRO services market and its likely evolution in the mid-long term.

Chapter 3 provides a general introduction to CROs, featuring insights on the historical evolution of such organizations, and legacy and contemporary trends in outsourcing activity. It also includes details on the various types of services offered by different CROs. Further, the chapter highlights the several advantages and risks associated in partnering with contract service providers, and also describes the role of CROs in the development of ATMPs.

Chapter 4 provides a detailed discussion on the business models that are commonly adopted by the biopharmaceutical industry for outsourcing. In addition, the chapter includes information on various factors that drive sponsors towards outsourcing and key parameters that sponsors must consider while choosing CROs at each phase of drug development process.

Chapter 5 provides a comprehensive view on the global landscape of cell and gene therapy CROs. It includes information related to over 70 CROs that claim to offer services for cell and gene therapies. It features an in-depth analysis of the players based on geographical location, company size, year of establishment, scale of operation, and range of services offered by clinical and preclinical CROs.

Chapter 6 features detailed profiles of key CROs offering cell and gene therapy related services, across different geographies. Each company profile includes a brief overview of the company, financial details / information (if available), information on service portfolios and a comprehensive future outlook.

Chapter 7 presents a benchmark analysis of the various players engaged in this domain. It highlights the capabilities of the companies in terms of their expertise across various services related to the development of cell and gene therapies. The analysis allows companies to compare their existing capabilities within and beyond their peer groups and identify opportunities to become more competitive in the industry.

Chapter 8 features a comprehensive clinical trial analysis of ongoing clinical studies for the evaluation of various cell and gene therapy product candidates. The analysis provides details related to cell and gene therapy clinical studies investigated across various geographies, based on the number of trials registered, start year of the clinical trial, current trial status, current phase of development, key therapeutic area (including indication-wise distribution), type of cell therapeutic (stem cells, T cells, dendritic cells, NK cells and tumor cells) and number of enrolled patients.

Chapter 9 provides an elaborate discussion and analysis of the various partnerships / collaborations that have been inked among the different players in the market. It includes a brief description on various types of partnerships models (such as outsourcing agreements, licensing agreements, service alliances, mergers and acquisitions) that have been employed by stakeholders in this domain since 2013. In addition, this chapter features details insights on mergers and acquisition in this domain.

Chapter 10 features a comprehensive market forecast analysis, highlighting the likely growth of cell and gene therapy contract research service market till the year 2030. We have provided inputs on the likely distribution of the opportunity by type of therapy (cell therapy and gene therapy), scale of operations (clinical and preclinical), type of therapeutic area (oncology and non-oncology) and across different regions (North America, Europe, Asia Pacific and rest of the world).

Chapter 11 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of cell and gene therapies research services, under a SWOT framework.

Chapter 12 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of this segment of the industry.

Chapter 13 is a collection of interview transcripts of the discussions that were held key stakeholders in the industry. We have presented details of interviews held with Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital) and Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado).

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 15 is an appendix, which provides the list of companies and organizations mentioned in the report.

Table of Contents

1 PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2 EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. An Overview of Contract Research Organizations (CROs)
3.2.1. Evolution of CROs
3.2.2. Modern CROs and Prevalent Outsourcing Trends
3.3. Services Offered by CROs
3.4. Classification of CROs
3.5. Advantages of Outsourcing to CROs
3.6. Risks Associated with Outsourcing to CROs
3.7. Role of CROs in the Development of ATMPs
3.8. Future Perspectives

4. GUIDE TO OUTSOURCING
4.1. Chapter Overview
4.2. Outsourcing Cell and Gene Therapy Research
4.3. Guiding Models of Outsourcing
4.3.1. Transactional Outsourcing Model
4.3.2. Performance-based Business Model
4.3.3. Outcome-based Business Model
4.3.4 Phase-dependent Outsourcing Models
4.4. Selecting a CRO Partner
4.4.1. Key Considerations
4.5. Role of CROs in Drug Development
4.5.1 Discovery and Preclinical Research
4.5.2 Early Clinical Research
4.5.3 Clinical Research and Laboratory Services
4.6. Conclusion

5. CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Cell and Gene Therapy CRO Services: Overall Market Landscape
5.2.1. Analysis by Location of Headquarters
5.2.2. Analysis by Company Size
5.2.3. Analysis by Scales of Operation
5.2.4 Analysis by Establishment Year
5.3. Cell and Gene Therapy: Clinical CROs
5.3.1. Analysis by Region
5.3.2. Analysis by Company Size
5.3.3. Analysis by Type of Therapy
5.3.4. Analysis by Type of Services
5.4. Cell and Gene Therapy: Preclinical CROs
5.4.1. Analysis by Region
5.4.2. Analysis by Company Size
5.4.3. Analysis by Type of Therapy
5.4.4. Analysis by Type of Services

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Players based in North America
6.2.1. Cato Research
6.2.1.1. Company Overview
6.2.1.2. Service Portfolio
6.2.1.3. Future Outlook
6.2.2. Charles River Laboratories
6.2.2.1. Company Overview
6.2.2.2. Financial Information
6.2.2.3. Services Portfolio
6.2.2.4. Future Outlook
6.2.3. Covance
6.2.3.1. Company Overview
6.2.3.2. Financial Information
6.2.3.3. Service Portfolio
6.2.3.4. Future Outlook
6.2.4. Creative Biolabs
6.2.4.1. Company Overview
6.2.4.2. Service Portfolio
6.2.4.3. Future Outlook
6.2.5. IQVIA
6.2.5.1. Company Overview
6.2.5.2. Financial Information
6.2.5.3. Service Portfolio
6.2.5.4. Future Outlook
6.2.6. Medpace
6.2.6.1. Company Overview
6.2.6.2. Financial Information
6.2.6.3. Service Portfolio
6.2.6.4. Future Outlook
6.3. Players based in Europe
6.3.1. Accelera
6.3.1.1. Company Overview
6.3.1.2. Service Portfolio
6.3.1.3. Future Outlook
6.3.2. BioniX
6.3.2.1. Company Overview
6.3.2.2. Service Portfolio
6.3.2.3. Future Outlook
6.3.3. JSB Solutions
6.3.3.1. Company Overview
6.3.3.2. Service Portfolio
6.3.3.3. Future Outlook
6.3.4. Quality Assistance
6.3.4.1. Company Overview
6.3.4.2. Financial Information
6.3.4.3. Service Portfolio
6.3.4.4. Future Outlook
6.4. Players based in Asia
6.4.1. CMIC Group
6.4.1.1. Company Overview
6.4.1.2. Financial Information
6.4.1.3. Service Portfolio
6.4.1.4. Future Outlook
6.4.2. Pharmaseed
6.4.2.1. Company Overview
6.4.2.2. Service Portfolio
6.4.2.3. Future Outlook

7. BENCHMARK ANALYSIS
7.1. Chapter Overview
7.2. Benchmark Analysis: Methodology
7.3. Benchmark Analysis: Peer Groups
7.3.1. Peer Group I
7.3.2. Peer Group II
7.3.3. Peer Group III
7.3.4. Peer Group IV
7.3.5. Peer Group V

8. CLINICAL TRIAL ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Cell Therapy: Distribution by Clinical Trials
8.3.1. Analysis by Trial Registration Year
8.3.2. Analysis by Type of Cell Therapy
8.3.3. Analysis by Phase of Development
8.3.4. Analysis by Type of Cell Therapy and Phase of Development
8.3.5. Analysis by Geography
8.3.6. Analysis by Type of Cell Therapy, Phase of Development and Geography
8.3.7. Analysis by Therapeutic Areas
8.3.8. Analysis by Therapeutic Area and Phase of Development
8.3.9. Analysis by Therapeutic Area, Phase of Development and Geography
8.4. Cell Therapy Clinical Trials: Analysis by Patients Enrolled
8.4.1. Analysis by Type of Cell Therapy
8.4.2. Analysis by Type of Cell Therapy and Geography
8.4.3. Analysis by Type of Cell Therapy, Phase of Development and Geography

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Cell and Gene Therapy CROs: List of Partnerships
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership Model
9.3.3. Analysis by Year and Type of Partnership Model
9.3.4. Analysis by Type of Therapy
9.3.5. Analysis by Type of Therapy and Type of Partnership Model
9.3.6. Most Active Players: Analysis by Number of Partnerships
9.3.7. Regional Distribution
9.3.8. Intercontinental and Intracontinental Agreements
9.4. Cell and Gene Therapy CROs: List of Mergers and Acquisitions
9.4.1. Analysis by Year
9.4.2. Geographical Activity
9.4.3. Ownership Change Matrix
9.4.4. Key Acquisitions: Deal Multiples

10. MARKET SIZING AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Forecast Methodology
10.3. Overall Cell and Gene Therapy CROs Market, 2018-2030
10.3.1. Cell and Gene Therapy CROs Market, 2018-2030: Distribution by Type of Therapy, 2018-2030
10.3.2. Cell and Gene Therapy CROs Market: Distribution by Scales of Operation, 2018-2030
10.3.3. Cell and Gene Therapy CROs Market: Distribution by Therapeutic Area, 2018-2030
10.3.4. Cell and Gene Therapy CROs Market: Distribution by Geography, 2018-2030
10.4. Cell and Gene Therapy CROs Market in North America, 2018-2030
10.4.1. Cell and Gene Therapy CROs Market in North America: Distribution by Therapeutic Area, 2018-2030
10.4.1.1. Cell and Gene Therapy CROs Market in North America for Oncological Disorders, 2018-2030
10.4.1.2. Cell and Gene Therapy CROs Market in North America for Cardiovascular Disorders, 2018-2030
10.4.1.3. Cell and Gene Therapy CROs Market in North America for Inflammatory Disorders, 2018-2030
10.4.1.4. Cell and Gene Therapy CROs Market in North America for Neurological Disorders, 2018-2030
10.4.1.5. Cell and Gene Therapy CROs Market in North America for Other Therapeutic Areas, 2018-2030
10.4.2. Cell and Gene Therapy CROs Market in North America: Distribution by Scale of Operation, 2018-2030
10.4.2.1. Cell and Gene Therapy CROs Market in North America for Clinical Operations, 2018-2030
10.4.2.2. Cell and Gene Therapy CROs Market in North America for Preclinical Operations, 2018-2030
10.5. Cell and Gene Therapy CROs Market in Europe, 2018-2030
10.5.1. Cell and Gene Therapy CROs Market in Europe: Distribution by Therapeutic Area, 2018-2030
10.5.1.1. Cell and Gene Therapy CROs Market in Europe for Oncological Disorders, 2018-2030
10.5.1.2. Cell and Gene Therapy CROs Market in Europe for Cardiovascular Disorders, 2018-2030
10.5.1.3. Cell and Gene Therapy CROs Market in Europe for Inflammatory Disorders, 2018-2030
10.5.1.4. Cell and Gene Therapy CROs Market in Europe for Neurological Disorders, 2018-2030
10.5.1.5. Cell and Gene Therapy CROs Market in Europe for Other Therapeutic Areas, 2018-2030
10.5.2. Cell and Gene Therapy CROs Market in Europe: Distribution by Scale of Operation, 2018-2030
10.5.2.1. Cell and Gene Therapy CROs Market in Europe for Clinical Operations, 2018-2030
10.5.2.2. Cell and Gene Therapy CROs Market in Europe for Preclinical Operations, 2018-2030
10.6. Cell and Gene Therapy CROs Market in Asia Pacific, 2018-2030
10.6.1. Cell and Gene Therapy CROs Market in Asia Pacific: Distribution by Therapeutic Area, 2018-2030
10.6.1.1. Cell and Gene Therapy CROs Market in Asia Pacific for Oncological Disorders, 2018-2030
10.6.1.2. Cell and Gene Therapy CROs Market in Asia Pacific for Cardiovascular Disorders, 2018-2030
10.6.1.3. Cell and Gene Therapy CROs Market in Asia Pacific for Inflammatory Disorders, 2018-2030
10.6.1.4. Cell and Gene Therapy CROs Market in Asia Pacific for Neurological Disorders, 2018-2030
10.6.1.5. Cell and Gene Therapy CROs Market in Asia Pacific for Other Therapeutic Areas, 2018-2030
10.6.2. Cell and Gene Therapy CROs Market in Asia Pacific: Distribution by Scale of Operation, 2018-2030
10.6.2.1. Cell and Gene Therapy CROs Market in Asia Pacific for Clinical Operations, 2018-2030
10.6.2.2. Cell and Gene Therapy CROs Market in Asia Pacific for Preclinical Operations, 2018-2030
10.7. Cell and Gene Therapy CROs Market in Rest of the World, 2018-2030
10.7.1. Cell and Gene Therapy CROs Market in Rest of the World: Distribution by Therapeutic Area, 2018-2030
10.7.1.1. Cell and Gene Therapy CROs Market in Rest of the World for Oncological Disorders, 2018-2030
10.7.1.2. Cell and Gene Therapy CROs Market in Rest of the World for Cardiovascular Disorders, 2018-2030
10.7.1.3. Cell and Gene Therapy CROs Market in Rest of the World for Inflammatory Disorders, 2018-2030
10.7.1.4. Cell and Gene Therapy CROs Market in Rest of the World for Neurological Disorders, 2018-2030
10.7.1.5. Cell and Gene Therapy CROs Market in Rest of the World for Other Therapeutic Areas, 2018-2030
10.7.2. Cell and Gene Therapy CROs Market in Rest of the World: Distribution by Scale of Operation, 2018-2030
10.7.2.1. Cell and Gene Therapy CROs Market in Rest of the World for Clinical Operations, 2018-2030
10.7.2.2. Cell and Gene Therapy CROs Market in Rest of the World for Preclinical Operations, 2018-2030

11. SWOT ANALYSIS
11.1. Chapter Overview
11.2. Strengths
11.3. Weaknesses
11.4. Opportunities
11.5. Threats
11.6. Concluding Remarks

12. CONCLUSION
12.1. Given the Growing Pipeline of Cell and Gene Therapies, the Demand for Contract Services is Anticipated to Increase
12.2. Presently, CROs Claim to Possess Superior Technical Expertise and Capabilities to Handle Challenging Aspects of Early and Clinical Stage Research
12.3. The Market for Cell and Gene Therapy Services is Concentrated in North America and Europe, the Key Innovation Hubs
12.4. Players have Entered into Strategic Collaborations to Support the Development of Pipeline Therapies or Expand their Capabilities
12.5. Owing to the Advantages Offered by Outsourcing, the Market for Cell and Gene Therapy R&D Services is Expected to be Worth Multi-Billion Dollars over the Next Decade

13. INTERVIEW AND SURVEY TRANSCRIPTS
13.1. Chapter Overview
13.2. Survey Transcript: Jessica Bliven (Director, Marketing and sales, Cato Research)
13.3. Interview Transcript: Dr. Xian-Bao Zhan (Professor of Medicine, Director, Department of Oncology, Changhai Hospital, Second Military Medical University)
13.4. Interview Transcript: Dr. Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Stages of Drug Development Process
Figure 3.2 Services Provided by CROs
Figure 3.3 Advantages of Outsourcing to CROs
Figure 3.4 Risk Associated with Outsourcing to CROs
Figure 3.5 Classification of ATMPs
Figure 3.6 Types of Cells Incorporated in CTMPs
Figure 4.1 Guiding Models for Outsourcing
Figure 4.2 Key Characteristics of Transactional Outsourcing Model
Figure 4.3 Key Characteristics of Performance-based Business Model
Figure 4.4 Key Steps Leading to Outcome-based Business Model
Figure 4.5 Steps to Consider before Outsourcing
Figure 4.6 Key Considerations to Select CROs
Figure 4.7 Role of a CRO in Different Phases of Drug Development
Figure 5.1 Cell and Gene Therapy CROs: Distribution by Geographical Location
Figure 5.2 Cell and Gene Therapy CROs: Distribution by Company Size
Figure 5.3 Cell and Gene Therapy CROs: Distribution by Scales of Operation
Figure 5.4 Cell and Gene Therapy CROs: Distribution by Establishment Year and Geography
Figure 5.5 Cell and Gene Therapy Clinical CROs: Distribution by Region
Figure 5.6 Cell and Gene Therapy Clinical CROs: Distribution by Location (Country-wise)
Figure 5.7 Cell and Gene Therapy Clinical CROs: Distribution by Company Size
Figure 5.8 Cell and Gene Therapy Clinical CROs: Distribution by Type of Therapy
Figure 5.9 Cell and Gene Therapy Clinical CROs: Distribution by Type of Services
Figure 5.10 Cell and Gene Therapy Clinical CROs: Distribution by Number of Services
Figure 5.11 Cell and Gene Therapy Preclinical CROs: Distribution by Region
Figure 5.12 Cell and Gene Therapy Preclinical CROs: Distribution by Location (Country-wise) 
Figure 5.13 Cell and Gene Therapy Preclinical CROs: Distribution by Company Size
Figure 5.14 Cell and Gene Therapy Preclinical CROs: Distribution by Type of Therapy
Figure 5.15 Cell and Gene Therapy Preclinical CROs: Distribution by Type of Services
Figure 5.16 Cell and Gene Therapy Preclinical CROs: Distribution by Number of Services
Figure 6.1 Cato Research: Service Portfolio
Figure 6.2 Charles River Laboratories: Annual Revenues, 2013-H1 2018 (USD Billion)
Figure 6.3 Charles River Laboratories: Service Portfolio
Figure 6.4 Covance: Annual Revenues, 2013-H1 2018 (USD Billion)
Figure 6.5 Covance: Non-clinical Service Portfolio
Figure 6.6 Covance: Clinical Service Portfolio
Figure 6.7 Creative Biolabs: Service Portfolio for CAR-T Therapy Development
Figure 6.8 Creative Biolabs: Service Portfolio for TCR Therapy Development
Figure 6.9 IQVIA: Annual Net Revenues, 2013-H1 2018 (USD Billion)
Figure 6.10 IQVIA: Distribution of Annual Revenue by Operating Business Segments (2017)
Figure 6.11 IQVIA: Service Portfolio
Figure 6.12 Medpace: Annual Service Revenues, 2013-H1 2018 (USD Million)
Figure 6.13 Medpace: Distribution of Net Service Revenue by Size of Client Company (2017)
Figure 6.14 Medpace: Service Portfolio
Figure 6.15 Medpace: Regulatory Affair Capabilities
Figure 6.16 Accelera: Areas of Expertise
Figure 6.17 BioniX: Service Portfolio
Figure 6.18 JSB Solutions: Service Portfolio
Figure 6.19 Quality Assistance: Annual Revenues, 2013-2017 (EUR Million)
Figure 6.20 Quality Assistance: Service Portfolio
Figure 6.21 CMIC Group: Annual Sales, 2013-2018 (JPY Billion)
Figure 6.22 CMIC Group: Non-clinical Service Portfolio
Figure 6.23 CMIC Group: Clinical Service Portfolio
Figure 6.24 Pharmaseed: Service Portfolio
Figure 7.1 Benchmark Analysis: Distribution of Companies by Year of Establishment and Region
Figure 7.2 Benchmark Analysis: Peer Group I
Figure 7.3 Benchmark Analysis: Peer Group II
Figure 7.4 Benchmark Analysis: Peer Group III
Figure 7.5 Benchmark Analysis: Peer Group IV
Figure 7.6 Benchmark Analysis: Peer Group V
Figure 8.1 Clinical Trial Analysis: Distribution by Start Year (2012-2017) and Geography
Figure 8.2 Clinical Trial Analysis: Distribution by Type of Cell Therapy
Figure 8.3 Clinical Trial Analysis: Distribution by Phase of Development
Figure 8.4 Clinical Trial Analysis: Distribution by Type of Cell Therapy and Phase of Development
Figure 8.5 Clinical Trial Analysis: Distribution by Type of Cell Therapy and Geography
Figure 8.6 Clinical Trial Analysis: Distribution by Type of Cell Therapy, Phase of Development and Geography
Figure 8.7 Clinical Trial Analysis: Distribution by Therapeutic Areas
Figure 8.8 Clinical Trial Analysis: Distribution by Therapeutic Area and Phase of Development
Figure 8.9 Clinical Trial Analysis: Distribution by Therapeutic Area, Phase of Development and Geography
Figure 8.10 Clinical Trial Analysis: Distribution of Patients Enrolled by Type of Cell Therapy
Figure 8.11 Clinical Trial Analysis: Distribution of Patient Enrolled by Type of Cell Therapy and Geography
Figure 8.12 Clinical Trial Analysis: Distribution of Patient Enrolled by Type of Cell Therapy, Phase of Development and Geography
Figure 9.1 Partnerships: Cumulative Trend by Year (2013-2018)
Figure 9.2 Partnerships: Distribution by Type of Partnership Model
Figure 9.3 Partnerships: Cumulative Trend by Year and Type of Partnership Model (2013-2018)
Figure 9.4 Partnerships: Distribution by Type of Therapy
Figure 9.5 Partnerships: Distribution by Type of Therapy and Type of Partnership Model
Figure 9.6 Partnerships: Most Active Players
Figure 9.7 Partnerships: Regional Distribution
Figure 9.8 Partnerships: Intercontinental and Intracontinental Distribution 
Figure 9.9 Mergers and Acquisitions: Cumulative Trend by Year (2013-2018)
Figure 9.10 Mergers and Acquisitions: Distribution by International and Local Agreements
Figure 9.11 Mergers and Acquisitions: Ownership Change Matrix
Figure 10.1 Overall Cell and Gene Therapy CROs Market, Base Scenario, 2018-2030 (USD Million)
Figure 10.2 Cell and Gene Therapy CROs Market: Distribution by Type of Therapy, 2018-2030 (USD Million)
Figure 10.3 Cell and Gene Therapy CROs Market: Distribution by Scales of Operation, 
2018-2030 (USD Million)
Figure 10.4 Cell and Gene Therapy CROs Market: Distribution by Therapeutic Area, 2018-2030 (%)
Figure 10.5 Cell and Gene Therapy CROs Market: Distribution by Geography, 2018 and 2030 (%)
Figure 10.6 Cell and Gene Therapy CROs Market in North America, Base Scenario, 2018-2030 (USD Million)
Figure 10.7 Cell and Gene Therapy CROs Market in North America for Oncological Disorders, 2018-2030 (USD Million)
Figure 10.8 Cell and Gene Therapy CROs Market in North America for Cardiovascular Disorders, 2018-2030 (USD Million)
Figure 10.9 Cell and Gene Therapy CROs Market in North America for Inflammatory Disorders, 2018-2030 (USD Million)
Figure 10.10 Cell and Gene Therapy CROs Market in North America for Neurological Disorders, 2018-2030 (USD Million)
Figure 10.11 Cell and Gene Therapy CROs Market in North America for Other Therapeutic Areas, 2018-2030 (USD Million)
Figure 10.12 Cell and Gene Therapy CROs Market in North America for Clinical Operations, 2018-2030 (USD Million)
Figure 10.13 Cell and Gene Therapy CROs Market in North America for Preclinical Operations, 2018-2030 (USD Million)
Figure 10.14 Cell and Gene Therapy CROs Market in Europe, Base Scenario, 2018-2030 (USD Million)
Figure 10.15 Cell and Gene Therapy CROs Market in Europe for Oncological Disorders, 2018-2030 (USD Million)
Figure 10.16 Cell and Gene Therapy CROs Market in Europe for Cardiovascular Disorders,2018-2030 (USD Million)
Figure 10.17 Cell and Gene Therapy CROs Market in Europe for Inflammatory Disorders, 2018-2030 (USD Million)
Figure 10.18 Cell and Gene Therapy CROs Market in Europe for Neurological Disorders, 2018-2030 (USD Million)
Figure 10.19 Cell and Gene Therapy CROs Market in Europe for Other Therapeutic Areas, 2018-2030 (USD Million)
Figure 10.20 Cell and Gene Therapy CROs Market in Europe for Clinical Operations, 2018-2030 (USD Million)
Figure 10.21 Cell and Gene Therapy CROs Market in Europe for Preclinical Operations, 2018-2030 (USD Million)
Figure 10.22 Cell and Gene Therapy CROs Market in Asia Pacific, Base Scenario, 2018-2030 (USD Million)
Figure 10.23 Cell and Gene Therapy CROs Market in Asia Pacific for Oncological Disorders, 2018-2030 (USD Million)
Figure 10.24 Cell and Gene Therapy CROs Market in Asia Pacific for Cardiovascular Disorders, 2018-2030 (USD Million)
Figure 10.25 Cell and Gene Therapy CROs Market in Asia Pacific for Inflammatory Disorders, 2018-2030 (USD Million)
Figure 10.26 Cell and Gene Therapy CROs Market in Asia Pacific for Neurological Disorders, 2018-2030 (USD Million)
Figure 10.27 Cell and Gene Therapy CROs Market in Asia Pacific for Other Therapeutic Areas, 2018-2030 (USD Million)
Figure 10.28 Cell and Gene Therapy CROs Market in Asia Pacific for Clinical Operations, 2018-2030 (USD Million)
Figure 10.29 Cell and Gene Therapy CROs Market in Asia Pacific for Preclinical Operations, 2018-2030 (USD Million)
Figure 10.30 Cell and Gene Therapy CROs Market in Rest of the World, Base Scenario, 2018-2030 (USD Million)
Figure 10.31 Cell and Gene Therapy CROs Market in Rest of the World for Oncological Disorders, 2018-2030 (USD Million)
Figure 10.32 Cell and Gene Therapy CROs Market in Rest of the World for Cardiovascular Disorders, 2018-2030 (USD Million)
Figure 10.33 Cell and Gene Therapy CROs Market in Rest of the World for Inflammatory Disorders, 2018-2030 (USD Million)
Figure 10.34 Cell and Gene Therapy CROs Market in Rest of the World for Neurological Disorders, 2018-2030 (USD Million)
Figure 10.35 Cell and Gene Therapy CROs Market in Rest of the World for Other Therapeutic Areas, 2018-2030 (USD Million)
Figure 10.36 Cell and Gene Therapy CROs Market in Rest of the World for Clinical Operations, 2018-2030 (USD Million)
Figure 10.37 Cell and Gene Therapy CROs Market in Rest of the World for Preclinical Operations, 2018-2030 (USD Million)
Figure 11.1 Cell and Gene Therapy CRO Services: SWOT Analysis
Figure 11.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 12.1 Cell and Gene Therapy CROs: Distribution by Company Size, Geography and Type of Therapy
Figure 12.2 Overall Cell and Gene Therapy CROs Market, Conservative, Base and Optimistic Scenario, 2018, 2024 and 2030 (USD Million)

List of Tables

Table 3.1 List of Approved ATMP Products
Table 5.1 Cell and Gene Therapy Clinical CROs: List of Companies
Table 5.2 Cell and Gene Therapy Clinical CROs: Details of Service Portfolio
Table 5.3 Cell and Gene Therapy Preclinical CROs: List of Companies
Table 5.4 Cell and Gene Therapy Preclinical CROs: Details of Service Portfolio
Table 6.1 Cato Research: Company Overview
Table 6.2 Cato Research: Future Outlook
Table 6.3 Charles River Laboratories: Company Overview
Table 6.4 Charles River Laboratories: Future Outlook
Table 6.5 Covance: Company Overview
Table 6.6 Covance: Future Outlook
Table 6.7 Creative Biolabs: Company Overview
Table 6.8 Creative Biolabs: Future Outlook
Table 6.9 IQVIA: Company Overview
Table 6.10 IQVIA: Future Outlook
Table 6.11 Medpace: Company Overview
Table 6.12 Medpace: Future Outlook
Table 6.13 Accelera: Company Overview
Table 6.14 Accelera: Future Outlook
Table 6.15 BioniX: Company Overview
Table 6.16 JSB Solutions: Company Overview
Table 6.17 Quality Assistance: Company Overview
Table 6.18 Quality Assistance: Future Outlook
Table 6.19 CMIC Group: Company Overview
Table 6.20 CMIC Group: Future Outlook
Table 6.21 Pharmaseed: Company Overview
Table 6.22 Pharmaseed: Future Outlook
Table 7.1 Benchmark Analysis: Peer Groups
Table 9.1 Cell and Gene Therapy CROs: List of Partnerships
Table 9.2 Cell and Gene Therapy CROs: List of Mergers and Acquisitions
Table 9.3 Key Acquisitions: Deal Multiples
Table 14.1 Cell and Gene Therapy CROs: Distribution by Geographical Location
Table 14.2 Cell and Gene Therapy CROs: Distribution by Company Size
Table 14.3 Cell and Gene Therapy CROs: Distribution by Scales of Operation
Table 14.4 Cell and Gene Therapy CROs: Distribution by Establishment Year and Geography
Table 14.5 Cell and Gene Therapy Clinical CROs: Distribution by Region
Table 14.6 Cell and Gene Therapy Clinical CROs: Distribution by Location (Country-wise)
Table 14.7 Cell and Gene Therapy Clinical CROs: Distribution by Company Size
Table 14.8 Cell and Gene Therapy Clinical CROs: Distribution by Type of Therapy
Table 14.9 Cell and Gene Therapy Clinical CROs: Distribution by Type of Services
Table 14.10 Cell and Gene Therapy Clinical CROs: Distribution by Number of Services
Table 14.11 Cell and Gene Therapy Preclinical CROs: Distribution by Region
Table 14.12 Cell and Gene Therapy Preclinical CROs: Distribution by Location (Country-wise) 
Table 14.13 Cell and Gene Therapy Preclinical CROs: Distribution by Company Size
Table 14.14 Cell and Gene Therapy Preclinical CROs: Distribution by Type of Therapy
Table 14.15 Cell and Gene Therapy Preclinical CROs: Distribution by Type of Services
Table 14.16 Cell and Gene Therapy Preclinical CROs: Distribution by Number of Services
Table 14.17 Charles River Laboratories: Annual Revenues, 2013-H1 2018 (USD Billion)
Table 14.18 Covance: Annual Revenues, 2013-H1 2018 (USD Billion)
Table 14.19 IQVIA: Annual Net Revenues, 2013-H1 2018 (USD Billion)
Table 14.20 IQVIA: Distribution of Annual Revenue by Operating Business Segments (2017)
Table 14.21 Medpace: Annual Service Revenues, 2013-H1 2018 (USD Million)
Table 14.22 Medpace: Distribution of Net Service Revenue by Size of Client Company (2017)
Table 14.23 Quality Assistance: Annual Revenues, 2013-2017 (EUR Million)
Table 14.24 CMIC Group: Annual Sales, 2013-2018 (JPY Billion)
Table 14.25 Benchmark Analysis: Distribution of Companies by Year of Establishment and Region
Table 14.26 Benchmark Analysis: Peer Group I
Table 14.27 Benchmark Analysis: Peer Group II
Table 14.28 Benchmark Analysis: Peer Group III
Table 14.29 Benchmark Analysis: Peer Group IV
Table 14.30 Benchmark Analysis: Peer Group V
Table 14.31 Clinical Trial Analysis: Distribution by Start Year (2012-2017) and Geography
Table 14.32 Clinical Trial Analysis: Distribution by Type of Cell Therapy
Table 14.33 Clinical Trial Analysis: Distribution by Phase of Development
Table 14.34 Clinical Trial Analysis: Distribution by Type of Cell Therapy and Phase of Development
Table 14.35 Clinical Trial Analysis: Distribution by Therapeutic Areas
Table 14.36 Clinical Trial Analysis: Distribution by Therapeutic Area and Phase of Development
Table 14.37 Clinical Trial Analysis: Distribution of Patients Enrolled by Type of Cell Therapy 
Table 14.38 Partnerships: Cumulative Trend by Year (2013-2018)
Table 14.39 Partnerships: Distribution by Type of Partnership Model
Table 14.40 Partnerships: Cumulative Trend by Year and Type of Partnership Model (2013-2018)
Table 14.41 Partnerships: Distribution by Type of Therapy
Table 14.42 Partnerships: Distribution by Type of Therapy and Type of Partnership Model
Table 14.43 Partnerships: Most Active Players
Table 14.44 Partnerships: Regional Distribution
Table 14.45 Mergers and Acquisitions: Cumulative Trend by Year (2013-2018)
Table 14.46 Mergers and Acquisitions: Distribution by International and Local Agreements
Table 14.47 Overall Cell and Gene Therapy CROs Market, Conservative, Base and Optimistic Scenario, 2018-2030 (USD Million)
Table 14.48 Cell and Gene Therapy CROs Market: Distribution by Type of Therapy, Base Scenario, 2018-2030 (USD Million)
Table 14.49 Cell and Gene Therapy CROs Market: Distribution by Scales of Operation, Base Scenario, 2018-2030 (USD Million)
Table 14.50 Cell and Gene Therapy CROs Market: Distribution by Therapeutic Area, 2018-2030 (%)
Table 14.51 Cell and Gene Therapy CROs Market: Distribution by Geography, 2018 and 2030 (%)
Table 14.52 Cell and Gene Therapy CROs Market in North America, Conservative, Base and Optimistic Scenario, 2018-2030 (USD Million)
Table 14.53 Cell and Gene Therapy CROs Market in North America for Oncological Disorders, 2018-2030 (USD Million)
Table 14.54 Cell and Gene Therapy CROs Market in North America for Cardiovascular Disorders, 2018-2030 (USD Million)
Table 14.55 Cell and Gene Therapy CROs Market in North America for Inflammatory Disorders, 2018-2030 (USD Million)
Table 14.56 Cell and Gene Therapy CROs Market in North America for Neurological Disorders, 2018-2030 (USD Million)
Table 14.57 Cell and Gene Therapy CROs Market in North America for Other Therapeutic Areas, 2018-2030 (USD Million)
Table 14.58 Cell and Gene Therapy CROs Market in North America for Clinical Operations, 2018-2030 (USD Million)
Table 14.59 Cell and Gene Therapy CROs Market in North America for Preclinical Operations, 2018-2030 (USD Million)
Table 14.60 Cell and Gene Therapy CROs Market in Europe, Conservative, Base and Optimistic Scenario, 2018-2030 (USD Million)
Table 14.61 Cell and Gene Therapy CROs Market in Europe for Oncological Disorders, 2018-2030 (USD Million)
Table 14.62 Cell and Gene Therapy CROs Market in Europe for Cardiovascular Disorders,2018-2030 (USD Million)
Table 14.63 Cell and Gene Therapy CROs Market in Europe for Inflammatory Disorders, 2018-2030 (USD Million)
Table 14.64 Cell and Gene Therapy CROs Market in Europe for Neurological Disorders, 2018-2030 (USD Million)
Table 14.65 Cell and Gene Therapy CROs Market in Europe for Other Therapeutic Areas, 2018-2030 (USD Million)
Table 14.66 Cell and Gene Therapy CROs Market in Europe for Clinical Operations, 2018-2030 (USD Million)
Table 14.67 Cell and Gene Therapy CROs Market in Europe for Preclinical Operations, 2018-2030 (USD Million)
Table 14.68 Cell and Gene Therapy CROs Market in Asia Pacific, Conservative, Base and Optimistic Scenario, 2018-2030 (USD Million)
Table 14.69 Cell and Gene Therapy CROs Market in Asia Pacific for Oncological Disorders, 2018-2030 (USD Million)
Table 14.70 Cell and Gene Therapy CROs Market in Asia Pacific for Cardiovascular Disorders, 2018-2030 (USD Million)
Table 14.71 Cell and Gene Therapy CROs Market in Asia Pacific for Inflammatory Disorders, 2018-2030 (USD Million)
Table 14.72 Cell and Gene Therapy CROs Market in Asia Pacific for Neurological Disorders, 2018-2030 (USD Million)
Table 14.73 Cell and Gene Therapy CROs Market in Asia Pacific for Other Therapeutic Areas, 2018-2030 (USD Million)
Table 14.74 Cell and Gene Therapy CROs Market in Asia Pacific for Clinical Operations, 2018-2030 (USD Million)
Table 14.75 Cell and Gene Therapy CROs Market in Asia Pacific for Preclinical Operations, 2018-2030 (USD Million)
Table 14.76 Cell and Gene Therapy CROs Market in Rest of the World, Conservative, Base and Optimistic Scenario, 2018-2030 (USD Million)
Table 14.77 Cell and Gene Therapy CROs Market in Rest of the World for Oncological Disorders, 2018-2030 (USD Million)
Table 14.78 Cell and Gene Therapy CROs Market in Rest of the World for Cardiovascular Disorders, 2018-2030 (USD Million)
Table 14.79 Cell and Gene Therapy CROs Market in Rest of the World for Inflammatory Disorders, 2018-2030 (USD Million)
Table 14.80 Cell and Gene Therapy CROs Market in Rest of the World for Neurological Disorders, 2018-2030 (USD Million)
Table 14.81 Cell and Gene Therapy CROs Market in Rest of the World for Other Therapeutic Areas, 2018-2030 (USD Million)
Table 14.82 Cell and Gene Therapy CROs Market in Rest of the World for Clinical Operations, 2018-2030 (USD Million)
Table 14.83 Cell and Gene Therapy CROs Market in Rest of the World for Preclinical Operations, 2018-2030 (USD Million)

List of Companies

The following companies and organizations have been mentioned in the report.

  1. 4Clinics
  2. Accelera
  3. AccelLAB
  4. Accord Research
  5. ACF Bioservices
  6. Adaptimmune 
  7. Advanced BioScience Laboratories
  8. Advanced Cell Diagnostics
  9. AGINKO Research
  10. Alpha Stem Cell Clinics
  11. Altasciences
  12. Altor BioScience
  13. Amulet Capital Partners
  14. Anterogen
  15. Apricot Designs
  16. Argint International
  17. Argos Therapeutics
  18. Ascendance Biotechnology
  19. Asterand Bioscience
  20. Aurigon
  21. Avance Biosciences
  22. BioAgilytix
  23. BioIVT
  24. BioniX
  25. Bio-Techne 
  26. Bioville
  27. BNP Paribas Fortis
  28. Bone Therapeutics
  29. Boston Biomedical Associates
  30. Brains On-Line
  31. BrainStorm Cell Therapeutics
  32. Cambridge Biomedical
  33. Capricor Therapeutics
  34. Cato BioVentures
  35. Cato Research
  36. Ce3
  37. Celgene
  38. Cell and Gene Therapy Catapult
  39. Cellectis
  40. Cellular Biomedicine Group
  41. CERB
  42. CHA Health Systems
  43. Charles River Laboratories
  44. Chiesi Farmaceutici
  45. Cinven
  46. Citoxlab
  47. City of Hope
  48. Clean Cells
  49. CMIC Group
  50. CombiGene
  51. Comparative Biosciences
  52. Covance
  53. Creative Biolabs
  54. CTI Clinical Trial and Consulting Services
  55. Dendreon
  56. DiscGenics
  57. Duke University
  58. Epeius Biotechnologies
  59. Evotec
  60. Farmacore Biotecnologia
  61. FGK Clinical Research
  62. Fibrocell
  63. GeneWerk
  64. GenoSafe
  65. Genprex
  66. GlaxoSmithKline 
  67. Global Centre for Medical Innovation
  68. Gradalis
  69. Green Cross LabCell
  70. Gsap
  71. HILDEBRAND PHARMA CONSULTING
  72. Histocell
  73. Holostem Terapie Avanzate
  74. Human Stem Cells Institute
  75. HuMurine Technologies
  76. Huntingdon Life Sciences
  77. i.e. Advising
  78. ICON
  79. ICRC-Weyer
  80. Imanis Life Sciences
  81. Immunicum
  82. ImmunoCellular Therapeutics
  83. Immunocore
  84. InSphero 
  85. Iovance Biotherapeutics
  86. IPM Biotech
  87. IQVIA
  88. Japan Tissue Engineering
  89. JSB Solutions
  90. Juno Therapeutics
  91. JW CreaGene
  92. Kite Pharma, a Gilead Sciences Company
  93. Kolon TissueGene
  94. KWS BioTest 
  95. LabCorp
  96. Linical Accelovance
  97. Lovelace Biomedical
  98. Medelis
  99. Median Technologies
  100. MEDINET
  101. MEDIPOST
  102. Medpace
  103. Mesoblast
  104. MI Bioresearch
  105. Midlands Independent Review Board
  106. Miltenyi Biotec
  107. Mitsubishi Tanabe Pharma
  108. MolMed
  109. MPI Research
  110. Nantes University Hospital
  111. NEC 
  112. Nerviano Medical Sciences
  113. Netherlands Cancer Institute
  114. NexImmune 
  115. Noble Life Sciences
  116. North American Science Associates (NAMSA)
  117. Northwest Therapeutics
  118. Novartis
  119. NovaTrials
  120. Novella Clinical
  121. Oncobiomed
  122. PAREXEL
  123. PathoQuest 
  124. Pfizer
  125. Pharmaceutical Product Development (PPD)
  126. Pharmaceutical Research Management
  127. Pharmacia
  128. Pharmahungary Group
  129. Pharmaseed
  130. Pharmicell
  131. Pilgrim Quality Solutions
  132. PRA Health Sciences
  133. PRC Clinical
  134. PrimeCell Therapeutics
  135. PSI CRO
  136. PSNResearch
  137. Quality Assistance
  138. Reliance Life Sciences
  139. Renova Therapeutics
  140. Research Dynamics Consulting Group
  141. Sanofi
  142. SCiAN Services
  143. Sciformix
  144. Seattle Genomics Laboratory
  145. Sermes CRO
  146. Sernova
  147. Shanghai Sunway Biotech
  148. Shenzhen Sibiono GeneTech
  149. SMS-oncology
  150. SNBL USA
  151. Société Régionale d'Investissement de Wallonie (SRIW)
  152. SOTIO
  153. Spark Therapeutics
  154. Spring Valley Laboratories
  155. Stemedica Cell Technologies
  156. Symbion Research International
  157. Syneos Health
  158. Synteract
  159. Taconic Biosciences
  160. Terumo
  161. TFS
  162. The Cell Factory
  163. The CLINICAL TRIAL Company Group
  164. Theradex Oncology
  165. TiGenix
  166. TransCell Science
  167. Translational Drug Development
  168. UBC
  169. Unilabs
  170. Vaccinogen
  171. Valois
  172. Veeva Systems
  173. Vericel
  174. Veristat
  175. Vivotecnia
  176. Wake Forest Innovations
  177. WCCT Global
  178. WCG Clinical
  179. WIL Research
  180. Worldwide Clinical Trials
  181. WuXi AppTec
     

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 3,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com